Scopus Açık Erişimli Yayınlar

Permanent URI for this collectionhttps://hdl.handle.net/11727/10760

Browse

Now showing 1 - 3 of 3

Evaluation of the nasal septal body in pediatric patients
(2021) Coban, Kubra; Ozer, Fulya; Akdogan, M. Volkan; 0000-0001-5381-6861; ABC-1809-2020
Objective: The nasal septal body (NSB) is a fusiform shaped dynamic structure and the widest part of the anterior septum. It consists of a thickened septal cartilage, bone, glandular, and vasoactive structures covered by mucous membranes. Hence, it plays a role in nasal airflow and humidification. This study evaluated the size of this structure in pediatric patients with allergic rhinitis and other sinonasal pathologies. Methods: The study was conducted at the Baskent University Hospital otolaryngology department between 2015 and 2019. A total of 117 children were enrolled, including 96 patients and 21 controls. The study group was divided into 3 sub-groups: group 1, with sinonasal pathologies and allergic rhinitis; group 2, with sinonasal pathologies only; and group 3, with allergic rhinitis only. The widest horizontal part of the NSB was measured on paranasal coronal computed tomography sections. Results: The mean NSB width in the patient and control groups were 1.00 +/- 0.19 cm and 0.90 +/- 0.16 cm, respectively. The NSB was significantly larger in the patient groups compared to the controls (p=0.032). There was no significant difference among the study sub-groups in terms of NSB width (p=0.215). A significant positive correlation was found between age and NSB in the patient and control groups (r=0.366, p=0.000 and r=0.632, p=0.002, respectively). There was a significant correlation between age and NSB in group 1 and group 2 (r=0.354, p=0.015 and r=0.447, p=0.010, respectively). Conclusion: The nasal septal body is significantly larger in children with comorbid sinonasal pathologies and allergic rhinitis compared to the control group.
Olfactory disorders in patients with mild to moderate COVID-19: spontaneous recovery in one-month follow up
(2021) Inan, Serhat; Ozer, Fulya; Erbek, Selim Sermed; Caylakli, Fatma; Odemis, Ilker; Kursun, Ebru; 0000-0003-2638-0163; 0000-0001-5381-6861; 0000-0001-8821-4481; 0000-0002-7333-2896; AFK-3690-2022; AAJ-1407-2021; AAG-2486-2022; ABC-1809-2020; AAP-7195-2020
Objective: In this study, we aimed to evaluate olfactory disorders (OD) and recovery processes in patients with coronavirus disease 2019 (COVID-19) infection at three time periods within one month from the time of diagnosis. Methods: A total of 96 patients with COVID-19 participated in the study. Self-reported changes in olfactory functions and their effects on quality of life (QoL) were evaluated using the National Health and Nutrition Examination Survey, the Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS), and Sino-Nasal Outcome Test (SNOT)-22. At the time of diagnosis, the patients were divided into three groups: anosmia, hyposmia, and no OD (control) group. Subsequently, olfactory functions were retested at the time of the first negative polymerase chain reaction (PCR) control test and one month from the time of diagnosis. Results: During the COVID-19 infection, 68.7% of patients had OD; of these, 37% had anosmia, and 29% had hyposmia. Dysgeusia was found in 44.8% of the patients. OD was the primary symptom in 10.8% of the patients. The QoL scores of those with anosmia and hyposmia were significantly lower than those with no OD in all three surveys (P <.05). The QOD-NS scores of those with OD lasting more than 14 days were significantly lower in all three surveys (P <.05). Of the patients with OD, 4.34% had no spontaneous recovery at the end of the first month. Conclusion: Recovery of OD is faster in patients with hyposmia than in those with anosmia. Although COVID-19related permanent OD is not commonly observed, treatment of OD that lasts for more than 15 days would be beneficial to avoid permanent sequelae.
Two Case of Rhino-Orbito-Cerebral Mucormicosis Developed After COVID-19 Infection
(2021) Demiroglu, Yusuf Ziya; Odemis, Ilker; Oruc, Ebru; Ozer, Fulya; Ulas, Burak; Canpolat, Emine Tuba; Yalcin, Cigdem; Sanli, Ozlem Oguc; 0000-0003-2638-0163; 0000-0001-5381-6861; 0000-0003-2638-0163; 0000-0002-6099-4786; 34666667; AAG-2486-2022; ABC-1809-2020; AFK-3690-2022
Coronavirus 2019 (COVID-19) infection causes excessive cytokine response and a decrease in cellular immune response and this increases susceptibility to fungal co-infections. Mucormycosis is a rare, life-threatening invasive fungal infection. In this report, two cases who developed rhino-orbito-cerebral mucormycosis shortly after having COVID-19 infection were presented. The first case was a 68-year old woman who admitted to our clinic with orbital cellulitis in her left eye and had a known diagnosis of asthma and rheumatoid arthritis. She was diagnosed with COVID-19 pneumonia 40 days ago, stayed in the intensive care unit for a long time, and received pulse steroid (1000 mg methylprednisolone), interleukin-1 (IL-1) inhibitor (anakinra) and broad-spectrum antibiotic treatments together with antiviral therapy during this period. The second case was a 63-year-old male patient with known diabetes mellitus, hypertension and retinitis pigmentosa, with a history of hospitalization in the intensive care unit due to COVID-19 pneumonia 20 days ago and received pulse steroid therapy during this period. He admitted to our clinic with the complaints of droopy right eyelid, swelling, nausea and vomiting. In both cases, paranasal sinus tomography findings were consistent with invasive sinusitis. Functional endoscopic sinus surgery was performed immediately in less than 16 hours from the first admission in both cases. Histopathological examination of the both cases revealed results consistent with mucormycosis. Mucorales spp. was isolated in sinus tissue culture of the second case taken during the operation. Both of the patients received liposomal amphotericin B. First case died on the 19th day of the treatment. Second case was discharged with full recovery after nine weeks of treatment. The suppression of cellular immunity during the COVID-19 infection, and the use of steroids and interleukin inhibitors in the treatment of severe cases may increase secondary invasive fungal infections. Therefore, clinicians should more frequently consider possible fungal infections in patients with COVID-19.